Literature DB >> 29187004

Personalized medicine for non-small cell lung cancer: where are we now and where can we go?

Doreen A Ezeife1, Natasha B Leighl1.   

Abstract

Entities:  

Keywords:  Personalized therapy; immunotherapy; molecular profiling; non-small cell lung cancer; targeted therapy

Year:  2017        PMID： 29187004     DOI： 10.1080/17476348.2018.1411805

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN： 1747-6348            Impact factor:   3.772


× No keyword cloud information.
  3 in total

1.  Characterization of lncRNA-Associated ceRNA Network to Reveal Potential Prognostic Biomarkers in Lung Adenocarcinoma.

Authors:  Yang Wang; Ruyi He; Lixin Ma
Journal:  Front Bioeng Biotechnol       Date:  2020-04-17

2.  A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.

Authors:  D Ross Camidge; Fabrice Barlesi; Jonathan W Goldman; Daniel Morgensztern; Rebecca Heist; Everett Vokes; Eric Angevin; David S Hong; Igor I Rybkin; Minal Barve; Todd M Bauer; Angelo Delmonte; Martin Dunbar; Monica Motwani; Apurvasena Parikh; Elysa Noon; Jun Wu; Vincent Blot; Karen Kelly
Journal:  JTO Clin Res Rep       Date:  2021-12-04

3.  Conditional Survival of Surgically Treated Patients with Lung Cancer: A Comprehensive Analyses of Overall, Recurrence-free, and Relative Survival.

Authors:  Dong Wook Shin; Jong Ho Cho; Jung Eun Yoo; Juhee Cho; Dong Woog Yoon; Genehee Lee; Sumin Shin; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Jae Ill Zo; Young Mog Shim
Journal:  Cancer Res Treat       Date:  2021-03-09       Impact factor: 4.679
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.